HealthDay News — Open-label placebo (OLP) provided with a treatment rationale is effective and safe for premenstrual syndrome (PMS), according to a study published online March 25 in BMJ ...
The FDA has approved Egrifta WR, a concentrated formulation (F8) of tesamorelin, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Lonapegsomatropin demonstrated efficacy outcomes superior to daily somatropin in treatment of pediatric growth hormone deficiency.
Graves disease had similar presentation but a more severe clinical course when isolated than when part of autoimmune polyglandular syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback